Go Pro
NASDAQ:CDT

CDT Equity Q2 2024 Earnings Report

CDT Equity logo
$2.93 +0.25 (+9.33%)
Closing price 07/31/2026 04:00 PM Eastern
Extended Trading
$2.80 -0.13 (-4.27%)
As of 07/31/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

CDT Equity EPS Results

Actual EPS
-$210,000.00
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

CDT Equity Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

CDT Equity Announcement Details

Quarter
Q2 2024
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

CDT Equity Earnings Headlines

CDT Equity (NASDAQ:CDT) Upgraded at Wall Street Zen
CDT Equity Expands Stake in Sarborg Via Warrants
Where to Put $100 Before Trump's New Tech Law Rolls Out
The Financial Times says a new tech law puts America 'on the verge of a financial revolution.' Yahoo Finance estimates it could unlock $400 trillion - but analyst Jeff Brown, who was consulted by Congressional offices on the legislation, believes the real figure could reach $2.6 quadrillion. Brown says this shift will pour onto a new type of investment exchange - and he's showing investors how to position themselves starting with just $100.tc pixel
CDT Equity announces 1-for-10 reverse stock split
See More CDT Equity Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like CDT Equity? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CDT Equity and other key companies, straight to your email.

About CDT Equity

Conduit Pharmaceuticals Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. The company was founded in 2019 and is based in San Diego, California. Conduit Pharmaceuticals Limited is a subsidiary of Corvus Capital Limited.

View CDT Equity Profile